Theradiag SA
PAR:ALTER

Watchlist Manager
Theradiag SA Logo
Theradiag SA
PAR:ALTER
Watchlist
Price: 1.26 EUR Market Closed
Market Cap: 16.4m EUR
Have any thoughts about
Theradiag SA?
Write Note

Theradiag SA
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Theradiag SA
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Theradiag SA
PAR:ALTER
Depreciation & Amortization
-€130k
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Edap Tms SA
NASDAQ:EDAP
Depreciation & Amortization
€1.9m
CAGR 3-Years
-3%
CAGR 5-Years
10%
CAGR 10-Years
5%
Biomerieux SA
PAR:BIM
Depreciation & Amortization
€233.9m
CAGR 3-Years
3%
CAGR 5-Years
5%
CAGR 10-Years
10%
Carmat SA
PAR:ALCAR
Depreciation & Amortization
€18.6m
CAGR 3-Years
1%
CAGR 5-Years
65%
CAGR 10-Years
37%
Visiomed Group SA
PAR:ALVMG
Depreciation & Amortization
€3.1m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
15%
Amplitude Surgical SA
PAR:AMPLI
Depreciation & Amortization
€11.2m
CAGR 3-Years
-15%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

Theradiag SA
Glance View

Market Cap
16.4m EUR
Industry
Health Care

Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.

ALTER Intrinsic Value
1.36 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Theradiag SA's Depreciation & Amortization?
Depreciation & Amortization
-130k EUR

Based on the financial report for Jun 30, 2023, Theradiag SA's Depreciation & Amortization amounts to -130k EUR.

What is Theradiag SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
0%

Over the last year, the Depreciation & Amortization growth was 0%.

Back to Top